DermTech, Inc. Stock

Equities

DMTK

US24984K1051

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:00:00 2024-04-26 EDT 5-day change 1st Jan Change
0.6031 USD +3.02% Intraday chart for DermTech, Inc. -6.35% -65.54%
Sales 2024 * 16.83M 23M Sales 2025 * 20.63M 28.2M Capitalization 20.88M 28.54M
Net income 2024 * -77M -105M Net income 2025 * -73M -99.78M EV / Sales 2024 * 1.24 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.01 x
P/E ratio 2024 *
-0.27 x
P/E ratio 2025 *
-0.29 x
Employees 207
Yield 2024 *
-
Yield 2025 *
-
Free-Float 47.95%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.02%
1 week-6.35%
Current month-14.09%
1 month-14.94%
3 months-53.25%
6 months-48.89%
Current year-65.54%
More quotes
1 week
0.58
Extreme 0.58
0.68
1 month
0.58
Extreme 0.58
0.71
Current year
0.58
Extreme 0.58
1.78
1 year
0.58
Extreme 0.58
3.90
3 years
0.58
Extreme 0.58
48.32
5 years
0.58
Extreme 0.58
84.49
10 years
0.58
Extreme 0.58
84.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 23-05-07
Director of Finance/CFO 46 19-07-31
Chief Tech/Sci/R&D Officer - 22-07-27
Members of the board TitleAgeSince
Director/Board Member 58 22-07-17
Director/Board Member 61 22-07-17
Director/Board Member 65 19-09-02
More insiders
Date Price Change Volume
24-04-26 0.6031 +3.02% 87,187
24-04-25 0.5854 -4.66% 179,181
24-04-24 0.614 -0.32% 71,712
24-04-23 0.616 +3.41% 168,697
24-04-22 0.5957 -7.50% 212,619

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm

More quotes
DermTech, Inc. is a molecular diagnostic company. The Company is engaged in developing and marketing non-invasive genomics tests to aid in the diagnosis and management of melanoma. Its technology enhances evaluation of lesions suspicious for melanoma using non-invasive sample collection and detecting genomic markers associated with melanoma to identify higher risk lesions or rule out melanoma with a 99% or higher negative predictive value (NPV). It offers DermTech Melanoma Test (the DMT), which is a non-invasive way to enhance evaluation of pigmented lesions suspicious for melanoma. Its genomics platform has been designed to work with its Smart Sticker, which provides an easy and non-invasive way to collect a skin sample, in contrast to the existing standard of care of using a scalpel to biopsy suspicious lesions. It also provides its research services and technology platform on a contract basis to pharmaceutical companies that use the technology to support their clinical trials.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.6031 USD
Average target price
2.043 USD
Spread / Average Target
+238.80%
Consensus